Sugi Predict

Sugi Predict / Compounds / SCHEMBL750055

SCHEMBL750055

SCHEMBL750055

COC(=O)c1cc(OC)c(O)c([N+](=O)[O-])c1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 1/20 0.61
▸ MAPT P10636 3/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ POLB P06746 2/20 0.52
▸ TDP1 Q9NUW8 2/20 0.52
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ RXFP1 Q9HBX9 1/20 0.51
▸ ABCB1 P08183 3/20 0.50
▸ ABCC1 P33527 3/20 0.50
▸ VCAM1 P19320 1/20 0.50
▸ TPMT P51580 1/20 0.50
▸ ERN1 O75460 1/20 0.50
▸ EGFR P00533 1/20 0.50
▸ JUN P05412 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ ESR1 P03372 1/20 0.48
▸ HPGD P15428 1/20 0.47
▸ FTO Q9C0B1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5924211 0.89 ESR1 (0.57) MAPTPOLBTDP1MEN1KMT2A
Hydrochloric Acid SCHEMBL9064842 0.87 ESR1 (0.56) MAPTPOLBTDP1MEN1KMT2A
SCHEMBL5598228 0.86 LMNA (0.66) TTRMAPTSMN1; SMN2POLBTDP1
SCHEMBL31059024 0.86 LMNA (0.66) TTRMAPTSMN1; SMN2POLBTDP1
SCHEMBL30740961 0.86 TPMT (0.59) MAPTMEN1KMT2AABCB1ABCC1
SCHEMBL3583434 0.86 CA12 (0.66) TTRMAPTSMN1; SMN2POLBTDP1
SCHEMBL31059025 0.86 LMNA (0.66) TTRMAPTSMN1; SMN2POLBTDP1
SCHEMBL8462586 0.86 TPMT (0.59) MAPTMEN1KMT2AABCB1ABCC1
SCHEMBL31447584 0.86 CA12 (0.66) TTRMAPTSMN1; SMN2POLBTDP1
SCHEMBL309910 0.85 ESR1 (0.56) TTRMAPTPOLBKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035341-A1 FTO INHIBITORS RPXDS CO LTD (CN) 2026-02-05 — — US disclosed
US-20250302842-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS Jubilant Epipad LLC 2025-10-02 — — US disclosed
US-20250263384-A9 REDOX-ACTIVE COMPOUNDS AND USES THEREOF CMBLU ENERGY AG (DE) 2025-08-21 — — US disclosed
US-12357639-B2 Heterocyclic compounds as pad inhibitors Jubilant Epipad LLC (US) 2025-07-15 — — US disclosed
EP-4561975-A1 FTO INHIBITORS RPXDS Co., Ltd (CN) 2025-06-04 — — EP disclosed
CN-119546566-A FTO inhibitors 瑞璞鑫(苏州)生物科技有限公司 2025-02-28 — — CN disclosed
CN-115697994-B Fused quinazoline derivative, preparation method thereof and application thereof in medicine 江苏恒瑞医药股份有限公司 2024-08-13 — — CN disclosed
US-20240156831-A1 HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS Jubilant Epipad LLC 2024-05-16 — — US disclosed
EP-3684767-B1 HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS Jubilant Epipad LLC (US) 2024-04-24 — — EP disclosed
EP-3684767-B1 HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS Jubilant Epipad LLC (US) 2024-04-24 — — EP disclosed
EP-1984377-A2 INHIBITORS OF TNF ALPHA , PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH Signal Pharmaceuticals LLC (US) 2008-10-29 — — EP disclosed
WO-2008119793-A1 PROCESS FOR THE PREPARATION OF ENTACAPONE AND INTERMEDIATES THEREOF Esteve Química, S.A. (ES) 2008-10-09 — — WO disclosed
WO-2008119793-A1 PROCESS FOR THE PREPARATION OF ENTACAPONE AND INTERMEDIATES THEREOF Esteve Química, S.A. (ES) 2008-10-09 — — WO disclosed
EP-1978014-A1 Process for the preparation of entacapone and intermediates thereof ESTEVE QUIMICA, S.A. (ES) 2008-10-08 — — EP disclosed
EP-1978014-A1 Process for the preparation of entacapone and intermediates thereof ESTEVE QUIMICA, S.A. (ES) 2008-10-08 — — EP disclosed
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 — — US disclosed
WO-2007140982-A1 SUBSTITUTED BENZOXAZOLES BAYER HEALTHCARE AG (DE) 2007-12-13 — — WO disclosed
WO-2007093507-A1 HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-23 — — WO disclosed
US-20070191603-A1 Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-08-16 — — US disclosed
WO-2007084560-A2 INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035341-A1 FTO INHIBITORS FTO, LDLR, GPR119 TTR 655/4885MAPT 1587/4885SMN1; SMN2 2140/4885
US-20250302842-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS NES, VHL, ETV6 TTR 771/4885MAPT 2514/4885SMN1; SMN2 43/4885
US-20240156831-A1 HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS PADI4, PADI2, PADI1 TTR 3952/4885MAPT 4416/4885SMN1; SMN2 3886/4885
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF TTR 2695/4885MAPT 3324/4885SMN1; SMN2 3598/4885
US-20250263384-A9 REDOX-ACTIVE COMPOUNDS AND USES THEREOF NOX4, NQO1, GPX1 TTR 2724/4885MAPT 1567/4885SMN1; SMN2 4506/4885
US-20070191603-A1 Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors CPT1A, CPT1B, CPT2 TTR 3953/4885MAPT 3162/4885SMN1; SMN2 2801/4885
US-12357639-B2 Heterocyclic compounds as pad inhibitors PADI4, PADI2, PADI1 TTR 3952/4885MAPT 4416/4885SMN1; SMN2 3886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.